Mineralys Therapeutics, Inc.NASDAQ: MLYS

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

· Issued by Mineralys Therapeutics, Inc.

On 6ix: 6ix.com/news/mineralys-therapeutics-presents-new-data-for-lorundrostat-at-the-american-heart-association-hypertension-scientific-sessions-2026

Watch Mineralys Therapeutics' latest callMineralys Therapeutics (NASDAQ:MLYS) Q2 2026 Earnings Call · Replay · Aug 11Read the transcript of Mineralys Therapeutics (NASDAQ:MLYS) Q2 2026 Earnings Call

- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of

Mineralys Therapeutics, Inc. on 6ix

Story so far

Earlier from Mineralys Therapeutics

Later from Mineralys Therapeutics

All Mineralys Therapeutics news releases